Viela Bio

Investors/Media

Press Releases

Press Releases

6.17.2019
Viela Bio Closes $75 Million Series B Financing
Funding to support regulatory filing and pre-commercial planning for lead product candidate, inebilizumab, and to advance development of additional clinical candidates targeting autoimmune and inflammatory diseases Financing led by HBM Healthcare Investments Gaithersburg, MD—June 17, 2019  – Viela
5.28.2019
Viela Bio Enters Strategic Collaboration with Hansoh Pharma to Develop and Commercialize Inebilizumab for Autoimmune Diseases and Hematologic Cancers in China
Partnership accelerates access to inebilizumab in China and supports the mission of both companies to bring transformative therapies to more patients around the world Viela Bio is eligible to receive an upfront collaboration fee and milestone payments of more than $220 million plus royalties on
5.07.2019
Viela Bio Presents Pivotal Study Results of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder in a Plenary Session at the American Academy of Neurology Annual Meeting
Pivotal Study Results of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder presented at the American Academy of Neurology Annual Meeting Viela Bio Presents Pivotal Study Results of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder in a Plenary Session at the
4.18.2019
Viela Bio Receives U.S. FDA Breakthrough Therapy Designation for Inebilizumab for Treatment of Neuromyelitis Optica Spectrum Disorder
U.S. FDA granted Breakthrough Therapy Designation for Inebilizumab for Treatment of Neuromyelitis Optica Spectrum Disorder Viela Bio Receives U.S. FDA Breakthrough Therapy Designation for Inebilizumab for Treatment of Neuromyelitis Optica Spectrum Disorder Designation based on positive primary
3.07.2019
Viela Bio Announces Pivotal Study Results of Inebilizumab in NMOSD to be Presented in a Plenary Session at the 2019 American Academy of Neurology Annual Meeting
Clinical results with inebilizumab in patients with NMOSD will be highlighted in an oral presentation during the plenary session at AAN 2019 Viela Bio Announces Pivotal Study Results of Inebilizumab in NMOSD to be Presented in a Plenary Session at the 2019 American Academy of Neurology Annual
1.03.2019
Viela Bio Announces Inebilizumab Achieved Primary and Key Secondary Endpoints in Pivotal Trial in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Largest controlled monotherapy trial in NMOSD demonstrates reduction in risk of attacks and reduction in worsening of disability in patients treated with inebilizumab Viela Bio Announces Inebilizumab Achieved Primary and Key Secondary Endpoints in Pivotal Trial in Patients with Neuromyelitis Optica
Displaying 11 - 16 of 16

Shareholder Tools